EmVenio Research Expands in the UK
With 10 mobile community research sites in the US, the move expands the organization’s international reach.
EmVenio Research, in collaboration with UK-based EMS Healthcare, will establish and operate commercial clinical trials in 10 mobile sites identified by EMS, across England, Wales, and Scotland. Each of the sites will be supported by a dedicated local workforce. EmVenio will be responsible for full clinical oversight, with principal and sub-investigators, and team leaders, and will oversee clinical trial operations and data management.
EmVenio currently operates research in 10 mobile community research sites across the United States.
Keith Austin, CEO of EMS Healthcare, said in press release, "A recent independent review of commercial clinical trials by Lord James O'Shaughnessy acknowledged the crucial role of mobile clinics in delivering trials with more diverse participation. We believe this initiative will attract more pharmaceutical sponsors to carry out trials, which will have a significant impact on both the U.K. economy and the health of our population."
Reference: EmVenio Research expands internationally with 10 research sites in the UK. DURHAM, N.C., June 20, 2023 /PRNewswire.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
